肺淋巴管平滑肌瘤病生物标志物的研究进展

Research progress on biomarkers of pulmonary lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病(pulmonary lymphangioleiomyomatosis,PLAM)是好发于育龄期女性的罕见慢性多系统肿瘤性疾病,其缺乏特异性的临床表现,需要可靠的生物标志物来实现PLAM的精准管理。近年来随着新兴生物标志物的出现,PLAM的检出率得到明显提升,可更好监测疾病进展,及时反馈疗效。这些新兴生物标志物主要包括血管内皮生长因子-D、维生素D结合蛋白、CT评分及前列腺素,该文就目前研究成果,对新兴生物标志物在PLAM诊断、预后评估、疾病监测方面的研究进展进行总结,旨在为PLAM的研究与治疗提供新思路。

Pulmonary lymphangioleiomyomatosis(PLAM)is a rare chronic multi-system neoplastic disease that occurs in women of childbearing age.It lacks specific clinical manifestations and requires reliable biomarkers to achieve precise management.In recent years,with the emergence of emerging biomarkers,the detection rate of PLAM has been significantly improved,which can better monitor disease progression and provide timely feedback on the efficacy.These emerging biomarkers mainly include vascular endothelial growth factor-D,vitamin D-binding protein,CT score and prostaglandins.This article will focus on the current research results,and summarize the research progress of emerging biomarkers in PLAM diagnosis,prognosis evaluation,and disease monitoring,aiming to provide new ideas for the research and treatment of PLAM.